Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD4 | P01730 | 14/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10232038 | 0.87 | CD4 (0.51) | CD4PKM | |
| SCHEMBL3394766 | 0.85 | ESR2 (0.55) | CD4PKM | |
| SCHEMBL16793968 | 0.82 | CD4 (0.47) | CD4MAPTRECQLPKM | |
| SCHEMBL1017072 | 0.81 | RYR2 (0.58) | CD4LMNASMN1; SMN2PKM | |
| SCHEMBL31287301 | 0.79 | MEN1 (0.55) | CD4LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL16572402 | 0.79 | MEN1 (0.55) | CD4LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL19216401 | 0.79 | TSHR (0.51) | CD4LMNARECQLPKM | |
| SCHEMBL3398104 | 0.79 | CD4 (0.60) | CD4MAPTSMN1; SMN2PKM | |
| SCHEMBL4011991 | 0.74 | MEN1 (0.64) | LMNAPKM | |
| SCHEMBL4044050 | 0.74 | RYR2 (0.57) | CD4LMNASMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170224852-A1 | BENZAZEPIN-1-OL-DERIVED PET LIGANDS WITH HIGH IN VIVO NMDA SPECIFICITY | WESTFAELISCHE WILHELMS-UNIVERSITAET (DE) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224852-A1 | BENZAZEPIN-1-OL-DERIVED PET LIGANDS WITH HIGH IN VIVO NMDA SPECIFICITY | OPRK1, GRIN1, OPRL1 | CD4 1453/4885LMNA 3642/4885MAPT 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.